Collaboration Target Designation Notice definition

Collaboration Target Designation Notice means a notice delivered by Jazz pursuant to Section 2.5.1 designating an Additional Collaboration Target, Replacement Target, or Revived Target, as applicable.
Sample 1Sample 2Sample 3
Collaboration Target Designation Notice has the meaning set forth in Section 4.2(c).
Sample 1

Examples of Collaboration Target Designation Notice in a sentence

  • Upon Jazz’s delivery of a Collaboration Target Designation Notice, the JSC will approve a mutually agreed upon new Work Plan, which will be added to the Research Plan and be deemed to be a Work Plan hereunder.

  • Upon Adagene’s receipt of the Collaboration Target Designation Notice, the respective Target shall be automatically designated a Collaboration Target under this Agreement, and the replaced Initial Target or replaced Collaboration Target added pursuant to Article 5 (Option Rights) shall cease to be a Collaboration Target under this Agreement.

  • Upon Adagene’s receipt of a Collaboration Target Designation Notice, such Target shall be automatically designated a Collaboration Target under this Agreement.

  • If the Gatekeeper notifies Sanofi that a Target nominated by Sanofi in a Target Nomination Notice is Available, Sanofi shall provide to Adagene a Collaboration Target Designation Notice within [***] after receipt of the Gatekeeper’s notice of Availability.

  • For the avoidance of doubt, all provisions applicable under this Agreement to Collaboration Targets, including the financial provisions set forth in Article 10, shall equally apply to Collaboration Targets designated under this Article 6, and shall cease to apply to the replaced Initial Target or to the replaced Collaboration Target added pursuant to Article 5 (Option Rights) upon receipt of the Collaboration Target Designation Notice by Adagene.

Related to Collaboration Target Designation Notice

  • Collaboration Target means the Initial Collaboration Targets set forth on Exhibit F and any Additional Target or Substitute Target that is selected in accordance with Section 3.3 of this Agreement.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Development Milestone Event has the meaning set forth in Section 7.2.1.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Development Milestone is defined in Section 5.3.

  • Development Plan has the meaning set forth in Section 3.2.

  • Research Period means the research period as described in the Commissioned Research Plan. In accordance with the provisions of this Agreement, in the event that the Agreement ended prior to the completion date of the research originally set, the date the Agreement ends shall be read as the research period.

  • Research Plan shall have the meaning set forth in Section 2.1.

  • Collaboration Term has the meaning set forth in Section 2.1(h).

  • Lead Compound means any compound of lead other than galena which, when treated in the manner described below, yields to an aqueous solution of hydrochloric acid a quantity soluble lead compound exceeding, when calculated as lead monoxide, five percent of the dry weight of the portion taken analysis.

  • Product Candidate means any pharmaceutical product developed, manufactured and/or tested by or on behalf of the Company that has not received a Regulatory Authorization for commercial distribution other than in connection with pre-clinical or clinical trials.

  • Additional SDU Study means a deliverability study that a Developer may elect to pursue as that term is defined in OATT Section 25 (OATT Attachment S). For purposes of Section 23.4.5 of this Attachment H, “Affiliated Entity” shall mean, with respect to a person or Entity:

  • Acquisition Target means any Person becoming a Subsidiary of the Company after the date hereof; any Person that is merged into or consolidated with the Company or any Subsidiary of the Company after the date hereof; or any Person with respect to which all or a substantial part of that Person’s assets are acquired by the Company or any Subsidiary of the Company after the date hereof.

  • Soft Target means a target that will suffer minimum damage and cause minimum damage to the subject vehicle in the event of a collision.

  • Development Schedule shall have the meaning set forth in Section 1.1.

  • Additional Indication means any indication other than the Initial Indication.

  • Commercialization Plan has the meaning set forth in Section 6.2.

  • Research Term has the meaning set forth in Section 3.2.

  • Development Milestone Payment shall have the meaning set forth in Section 9.2(a).

  • Research Program Term has the meaning set forth in Section 2.2.

  • JDC has the meaning set forth in Section 3.2.

  • JSC has the meaning set forth in Section 3.1.

  • Replacement Candidate means any Candidate Introduced by the Agency to the Client to fill the Engagement following the Introduction of another Candidate whose Engagement either did not commence or was terminated during the first 12 weeks of the Engagement;

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.

  • JRC has the meaning set forth in Section 2.2.